News Headline Summary

FDA expands Johnson & Johnson (JNJ) Zyriga's use for late-stage prostate cancer

Reaction details (13:23)

- Johnson & Johnson's shares are unmoved by this latest commentary from Johnson & Johnson; trades USD 70.72 last (+0.4%).

10 Dec 2012 - 13:21 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: